Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:26:32 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:UCBJY - UCB S.A. UNSP ADR EACH REPR 0.5 ORD - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
UCBJY - Qnot subscribed66.475-0.367632-0.536.82,43311266.23  66.63  66.2365.55  34.8515:45:09Apr 0415 min RT 2¢

Recent Trades - Last 10 of 112
Time ETExPriceChangeVolume
15:45:09Q66.565-0.73551
15:45:08Q66.565-0.73533
15:45:04Q66.565-0.7351
15:45:03Q66.565-0.73510
15:45:03Q66.565-0.73525
15:45:01Q66.565-0.2776321,100
15:45:01Q66.565-0.277632142
15:45:01Q66.5987-0.701388
15:45:01Q66.475-0.367632154
15:45:01Q66.7855-0.514565

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-04 07:00U:UCBJYNews ReleaseFDA Accepts Supplemental Biologics License Applications for BIMZELX(TM) (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
2024-03-09 12:00U:UCBJYNews ReleaseFirst Presentation of Year 4 BIMZELX(TM) (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
2024-03-08 12:00U:UCBJYNews ReleaseBIMZELX(TM) 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
2024-02-28 07:03U:UCBJYNews ReleaseUCB on Growth Path for a Decade Plus
2024-01-03 07:00U:UCBJYNews ReleaseZILBRYSQ ‚ ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
2023-12-02 07:00U:UCBJYNews ReleaseUCB presents new data about the real-world experience of FINTEPLA ‚ ® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
2023-12-01 07:00U:UCBJYNews ReleaseUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
2023-11-14 07:00U:UCBJYNews ReleaseUCB Announces U.S. Availability of BIMZELX ‚ ® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
2023-11-11 07:00U:UCBJYNews ReleasePost Hoc Analysis Showed CIMZIA ‚ ® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
2023-11-10 07:00U:UCBJYNews ReleaseUCB Presents New Five-Year Data on BIMZELX ‚ ® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
2023-11-01 07:00U:UCBJYNews ReleaseUCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
2023-10-31 07:00U:UCBJYNews ReleaseNAYZILAM ‚ ® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
2023-10-18 07:00U:UCBJYNews ReleaseBIMZELX ‚ ® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
2023-10-17 18:34U:UCBJYNews ReleaseUCB announces U.S. FDA approval of ZILBRYSQ ‚ ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
2023-10-13 12:00U:UCBJYNews ReleaseUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
2023-10-12 12:20U:UCBJYNews ReleasePhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
2023-10-04 13:06U:UCBJYNews ReleaseUCB presents late-breaking posters at Child Neurology Society Meeting
2023-07-21 07:00U:UCBJYNews ReleaseUCB announces U.S. availability of RYSTIGGO ‚ ® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
2023-06-27 07:00U:UCBJYNews ReleaseUCB announces U.S. FDA approval of RYSTIGGO ‚ ® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis